Skip to content

Study · Randomized controlled trial · n = 103 · 2020

6 results

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND

European urology6 Apr 2020Cited by 70 (Europe PMC)

PMID32273183 (opens in a new tab)DOI10.1016/j.eururo.2020.03.001 (opens in a new tab)PepBankPUB-32273183
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Three months after treatment discontinuation, testosterone recovered in 16% of degarelix recipients versus 52% of relugolix recipients, without significance testing.

    In plain wordsTestosterone recovered in 16% after degarelix versus 52% after relugolix, without significance testing.

    Peptide
    Degarelix
    Outcome
    Not applicableTestosterone recovery after discontinuation
    Study

    n = 103

    Comparator
    Relugolix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Testosterone recovery
    16%
    degarelix
    Testosterone recovery
    52%
    relugolix

    Source sentences

    Summary
    Three months after discontinuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone recovery (statistical significance of differences not tested).
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.
  2. 02HumanRandomized controlled trialSafety outcome

    In prostate cancer patients receiving radiotherapy, hot flush occurred in 61% with degarelix versus 57% with relugolix.

    In plain wordsHot flush occurred in 61% of prostate cancer patients receiving degarelix versus 57% receiving relugolix.

    Peptide
    Degarelix
    Outcome
    Not applicableHot flush
    Study

    n = 103

    Comparator
    Relugolix
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Hot flush
    61%
    degarelix
    Hot flush
    57%
    relugolix

    Source sentences

    Summary
    The most common adverse event was hot flush (relugolix 57%; degarelix 61%).
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.
  3. 03HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients receiving radiotherapy, PSA levels decreased during degarelix treatment, as in the relugolix group.

    In plain wordsIn prostate cancer patients receiving radiotherapy, PSA decreased during degarelix treatment, as with relugolix.

    Peptide
    Degarelix
    Outcome
    DecreasePSA levels
    Study

    n = 103

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    During treatment, PSA levels and prostate volumes were reduced in both groups.
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.
  4. 04HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients receiving radiotherapy, prostate volume decreased during degarelix treatment, as in the relugolix group.

    In plain wordsIn prostate cancer patients receiving radiotherapy, prostate volume decreased during degarelix treatment, as with relugolix.

    Peptide
    Degarelix
    Outcome
    DecreaseProstate volume
    Study

    n = 103

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    During treatment, PSA levels and prostate volumes were reduced in both groups.
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.
  5. 05HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients receiving radiotherapy, degarelix achieved an 89% castration rate at the 1.73 nmol/l threshold.

    In plain wordsIn prostate cancer patients receiving radiotherapy, degarelix achieved an 89% castration rate.

    Peptide
    Degarelix
    Outcome
    Not applicableCastration rate below 1.73 nmol/l
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Castration rate
    89%
    degarelix, 1.73 nmol/l threshold

    Source sentences

    Summary
    Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively.
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.
  6. 06HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients receiving radiotherapy, degarelix achieved a 68% castration rate at the 0.7 nmol/l threshold.

    In plain wordsIn prostate cancer patients receiving radiotherapy, degarelix achieved profound testosterone suppression in 68%.

    Peptide
    Degarelix
    Outcome
    Not applicableProfound castration rate
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Profound castration rate
    68%
    degarelix, 0.7 nmol/l threshold

    Source sentences

    Summary
    Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively.
    3 context sentences
    Summary · context
    A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.
    Summary · context
    Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).
    Summary · context
    No formal statistical comparisons with degarelix were planned.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.